Jefferies Reiterates Their Hold Rating on Repligen Corp

By Carrie Williams

In a report issued on September 12, Eun Yang from Jefferies reiterated a Hold rating on Repligen Corp (NASDAQ: RGEN), with a price target of $40. The company’s shares opened today at $43.09.

According to, Yang is a 4-star analyst with an average return of 5.8% and a 52.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, DBV Technologies SA – American, and Iovance Biotherapeutics Inc.

Repligen Corp has an analyst consensus of Moderate Buy, with a price target consensus of $40.

The company has a one year high of $46.81 and a one year low of $26.16. Currently, Repligen Corp has an average volume of 323.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Repligen Corp. engages on the development, production and commercialization of products used in the process of manufacturing biological drugs. It offers upstream solutions, downstream solutions, and analytics. The upstream solutions offers XCell ATF System and cell culture supplements.